Molecular Imaging News and Research

RSS

ART to report on its molecular imaging products research at the World Molecular Imaging Congress

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at poster sessions at the World Molecular Imaging Congress (WMIC), being held at the Palais des congres in Montreal, Canada, from September 23 to 26, 2009.

22 Sep 2009

Positron to promote its Attrius cardiac optimized PET scanner at the MedAxiom Fall Conference

Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will attend MedAxiom’s Fall Conference in Dana Point, California September 23rd, 2009 to promote their cardiac optimized PET scanner, the Attrius™ (www.medaxiom.com).

19 Sep 2009

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.

17 Sep 2009

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

11 Sep 2009

SNM survey evaluates the impact of the worldwide medical isotope shortage

SNM recently conducted a survey of nuclear pharmacies-pharmacies that supply the critical radioisotope Technetium-99m, which is used in more than 16 million nuclear medicine tests each year in the United States-to assess, anecdotally, the impact of the worldwide medical isotope shortage. According to the survey, 60 percent of radiopharmacies have been impacted by the most recent shortage. Technetium-99m is a product of Molybdenum-99, which has been in short supply recently.

9 Sep 2009

SoftScan clinical results from a breast cancer treatment monitoring study to be presented at IEEE International Conference

ART Advanced Research Technologies Inc. (ART) (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Dr. Gregory Czarnota, MD, PhD, Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health Sciences Centre, will be presenting SoftScan® clinical results from a breast cancer treatment monitoring study, at the IEEE Engineering in Medicine and Biology Society 31st Annual International Conference in Minneapolis, Minn.

5 Sep 2009

NSF grants funds to develop next-generation nano-CT imaging system

In 1991, Ge Wang produced the first paper on spiral cone-beam computed tomography (CT), now an imaging technique used in the mainstream of the medical CT field. Today, Wang, known as a pioneer in this field, and his colleagues have been awarded more than $1.3 million from the National Science Foundation (NSF) to develop the next-generation nano-CT imaging system, which promises to greatly reduce the required dose of radiation.

4 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Positron forges Agent Agreement with Technology Imaging Services

Positron Corporation (OTCBB:POSC) (the “Company”), a molecular imaging solutions company focused on Nuclear Cardiology, announced today that they have executed an Agent Agreement with TIS – Technology Imaging Services. TIS offers a wide range of solutions for Nuclear Cardiology, Oncology, and Cardiac PET, including hot lab set up and products.

26 Aug 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

...

25 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

GE Global Research Biosciences technology celebrated fifth anniversary

From creating a new business in digital pathology to developing next generation diagnostic imaging agents and life sciences tools that are breaking new ground in the detection and treatment of disease, the Biosciences technology organization at GE Global Research today celebrated its fifth anniversary.

6 Aug 2009

New microchip technology may accelerate drug discovery for cancer, other diseases

Flasks, beakers and hot plates may soon be a thing of the past in chemistry labs. Instead of handling a few experiments on a bench top, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results - literally shrinking the lab down to the size of a thumbnail.

From Siemens Healthineers 3 Aug 2009

Current diagnostic tests for ovarian cancer woefully ineffective

A new study finds that in order to make a significant dent in the mortality rate for the deadly cancer, the tests would have to be able to detect tumors of less than 1 cm in diameter, or about 200-times smaller in mass than those currently used to assess potential new tests. Still, if that hurdle can be overcome, there is good reason to believe that testing could make a big difference: The window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years.

28 Jul 2009

Early detection of pancreatic cancer closer thanks to multifunctional nanoparticles

Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

28 Jun 2009

Positron emission tomography scans may improve the accuracy of dementia diagnosis

A new study shows that the use of positron emission tomography (PET) scans may improve the accuracy of dementia diagnoses early in disease onset for more than one out of four patients. The results were presented at SNM's 56th Annual Meeting.

15 Jun 2009

New imaging analysis method predicts brain tumor survival

As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found.

20 Apr 2009

Scientists use non-invasive approach to watch chemo drug working inside the living body in real time

For many cancer patients, chemotherapy can be worse than cancer itself.

2 Feb 2009

Researchers refine breast cancer identification

Not all breast cancers are the same, and not all will have fatal consequences.

27 Jan 2009

Molecular imaging enables earlier, individualized treatment of thyroid cancer

In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.

5 Jan 2009